An Australian company with an exclusive license to a number of rare cannabis strains is putting its plant to the test. Through a study, the company is now researching the effects of rare cannabinoids on autism.
This is a very exciting and novel approach to the treatment of autism spectrum disorder.Neurotech International (NTI)
Safety and compatibility
Neurotech International (NTI) aims to use the study to determine and evaluate the safety and tolerability of its products for treating symptoms associated with autism in children.
According to a report, the company is currently working on an open clinical study. Subjects of the study are 20 children aged 5 to 17 who suffer from autism spectrum disorder (ASD).
First research of a cannabis extract in children with ASD.
According to the release, this study is the first research of a full-spectrum cannabis extract in children with ASD, with the extract containing less than 0.3% THC.
Professor Michael Fahey, head of pediatric neurology at Monash Children’s Hospital, is monitoring the results with senior clinical autism and behavioral psychologists over a 16-week period. The effects of cannabis on factors such as concentration, agitation, irritability and overall quality of life are observed and recorded. The resulting scores will then be used to design future studies of treatment in children with ASD.
Important aspect in the treatment of children
Medicinal cannabis has the potential to provide this treatment, but only NTI/Dolce naturally derived strains offer full-spectrum CBDs with little to no THC, an important consideration when treating childrenBrian Leedman, chairman of Neurotech
The NTI strains contain rare cannabinoids, such as CBDP and CBDB, in addition to large amounts of CBD. Leedman continues:
This is a very exciting and novel approach to the treatment of ASD, for which there is the need for safe, effective therapies with no side effects that can improve a patient’s quality of life.